Health Canada accepts Penthrox regulatory submission for review

Medical Developments International (MVP) has announced that Health Canada has accepted its submission for the Penthrox methoxyflurane inhaler, triggering a $250,000 Canadian milestone payment to MVP from Purdue Pharma Canada.

In September 2016, MVP announced that Purdue Pharma Canada would pay $3 million Canadian for Canadian rights to Penthrox for the treatment of moderate to severe pain in trauma patients.

MVP CEO John Sharman commented, “This is another positive step towards globalizing Penthrox.”

Read the MVP press release.